Navigation Links
Symphony Medical Changes Name to CardioPolymers, Inc.
Date:7/22/2009

LAGUNA HILLS, Calif., July 22 /PRNewswire/ -- Symphony Medical, Inc., a development-stage company focused on novel biopolymer implant therapies to treat cardiac abnormalities, announced today that it has changed the name of the corporation to CardioPolymers, Inc.

CardioPolymers, Inc. Chief Executive Officer Raymond W. Cohen said, "The name change, which is effective immediately, better reflects our focus on employing natural biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle."

CardioPolymers is currently sponsoring a human clinical study of its patented flagship technology Algisyl-LVR(R) at world-class centers in Europe, including the German Heart Center in Munich where the first three patients were successfully treated.

Algisyl-LVR is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in which the heart becomes weakened and enlarged, and cannot pump blood efficiently. The procedure involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to re-shape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.

About CardioPolymers, Inc.

CardioPolymers, Inc., a Delaware Corporation (formerly known as Symphony Medical) was founded in 2003 and is headquartered in Orange County, California. The Company is privately held and backed by venture investors Johnson & Johnson, Domain Associates, Morgenthaler Ventures, Triathlon Medical Ventures and Fjord Ventures. The development stage company is developing proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders.

For more information on CardioPolymers, Inc. please visit our website at

www.symphonymed.com

    Contact:  Matt Clawson
              Allen & Caron Inc
              949-474-4300
              matt@allencaron.com


'/>"/>
SOURCE CardioPolymers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Symphony Managemnt Consulting Hires New Solutions Director
3. Angiotech and Symphony Medical Announce Licensing Agreement
4. Environmental Tectonics Corporation Announces Promotion of Don R. Webber to VP of Sales for their BioMedical Division
5. Regado Biosciences Expands Medical Advisory Board
6. BioMS Medical announces second quarter 2009 results
7. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
8. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
9. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
10. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
11. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... provide essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB ... V E FPGA into a compact business-card sized form factor suitable for prototyping, ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project Muscular ... to end Duchenne muscular dystrophy (Duchenne) , today ... New Jersey Institute of Technology (NJIT) and Talem Technologies ... of robotic technology to assist people living with ... NJIT,s technology – an embedded computer, software, a force ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and ... SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at ... was an anterior cervical discectomy and fusion on a 42 year old female ...
Breaking Biology Technology:
(Date:1/19/2017)... Jan. 19, 2017 Sensory Inc ... and security for consumer electronics, and i ... systems and cybersecurity solutions, today announced a global ... financial institutions worldwide to bolster security of data ... secure user authentication platforms they offer, innerCore now ...
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
(Date:1/12/2017)... Oregon and PUNE, India , January 12, 2017 /PRNewswire/ ... Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market ... of 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):